论文部分内容阅读
2007年德国Merck公司宣布艾滋病病毒(HIV)疫苗失败后,艾滋病疫苗研究陷入低谷。2011年在泰国进行的RV144疫苗显示受试人群获得了31.2%的保护[1],这个出人意料的结果让研究者重燃信心,即有效的HIV疫苗是可能的。随后,抗HIV-1中和抗体产生条件、靶点、抗体结构及运用等,成为了近年的研究热点。通常,在2~3年的HIV-1慢性感染患者中,约20%感染者能产生抗HIV-1的广谱性中和抗体(BnAbs)[2]。过去几年,特异性单克隆抗体(mAb)的高效筛选、宿主产生BnAbs的分析、对表位结构的理解和带特异性表位假病毒的中和实验
AIDS vaccine research fell into doldrums after Merck in Germany announced the failure of the HIV vaccine in 2007. The RV144 vaccine in Thailand in 2011 showed a 31.2% protection for the study population [1], a surprising result that has rekindled researchers that a valid HIV vaccine is possible. Subsequently, the conditions of anti-HIV-1 neutralizing antibody production, target, antibody structure and application, etc., has become a research hot spot in recent years. Often, about 20% of HIV-1-infected patients with 2-3 years of age develop a broad-spectrum anti-HIV-1 neutralizing antibody (BnAbs) [2]. Over the past few years, efficient screening of specific monoclonal antibodies (mAb), analysis of host-generated BnAbs, understanding of epitope structures, and neutralization experiments with specific epitope pseudovirions